KalVista Pharmaceuticals (“KalVista”), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
Month: August 2011
KalVista Pharmaceuticals Launched With 8 Million In Series A Funding To Develop Novel Class Of Drugs For Diabetic Macular Edema
KalVista Pharmaceuticals (“KalVista”), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
KalVista Pharmaceuticals Launched With 8 Million In Series A Funding To Develop Novel Class Of Drugs For Diabetic Macular Edema
KalVista Pharmaceuticals (“KalVista”), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
Kellogg Researcher Helping Eye Care Providers Better Assess Driving In Older Adults
Drivers over age 65 are the fastest-growing segment of the driving population, and their eye care providers-ophthalmologists and optometrists-are playing an increasingly important role in assessing their ability to drive safely.
MIVI-TRUST Outcomes Strengthen Support Of Ocriplasmin For Vitreomacular Adhesion
Ocriplasmin may become the first pharmacologic option for patients with vitreomacular adhesion, according to two presentations here.
Landmark 8 Millionth U.S. Patent Awarded to Second Sight Medical’s Retinal Prosthesis
On July 31, 1790, the first United States patent was issued to Samuel Hopkins for a process for making potash. Millions of patents have been issued in the 221 years since, many of them related to medical devices and technologies. This week, the United States Patent and Trademark Office (USPTO) announced the awarding of the 8 millionth patent – (Read more...)
NICE agrees to review appeal against its decision on ranibizumab for diabetic macular oedema
Source: PharmaLive
Area: News
According to a PharmaLive report, the National Institute for Health and Clinical Excellence (NICE) has agreed to review an appeal against its preliminary decision not to recommend ranibizumab for the treatment of visual i…
Abbott Receives CE Mark For Healon EndoCoat Protective Gel For Cataract Surgery
Abbott announced today that it has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the European CE Mark of Healon EndoCoat OVD.
Sosei To Receive Grant From NEDO’s FY2011 Innovation Promotion Programme For Development Of Innovative Ophthalmic Solutions
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. (“Activus”) is to receive a grant for its “Development of Innovative Ophthalmic Solutions” from the New Energy and Industrial Technology Development Organizati…
Volk Pictor Portable Imager At Vision West
Mentor, Ohio (August 19, 2011) – Volk Optical’s new Pictor digital imaging device will demonstrate its ease of use outside the office at Vision West September 22 – 24, 2011 at the Sands Expo and Convention Center (Las Vegas, Nev.). At Volk’s exhibit in…
ThromboGenics Announces New Phase III Ocriplasmin Data Presented At The 2011 Annual Meeting Of The American Society Of Retina Specialists (ASRS)
New data presented by leading retinal specialists Dr Pravin U. Dugel, MD (Phoenix, AZ) and Dr Peter K. Kaiser, MD (Cleveland, OH)
Time-release corticosteroid implant effective in treating uveitis
A team of researchers comparing the two leading treatment approaches for the eye condition uveitis, which is the fifth leading cause of blindness in the US, have found that a time-release corticosteroid implant placed surgically in the eye is similarly…
Vision Problems Common After Glaucoma Surgery
More than half of people getting a certain type of glaucoma surgery may suffer from temporary, sometimes severe vision loss afterwards, suggests a new study. A smaller proportion — about 8 in every 100 — could have some degree of permanent vision los…
Short-Term Dark Adaptation May Be More Reliable In Identifying Primary Angle-Closure Suspects
Assessment of the anterior chamber angle configuration may be more reliable if performed after a short-term dark adaptation of 3 minutes, a study found.
Short-Term Dark Adaptation May Be More Reliable In Identifying Primary Angle-Closure Suspects
Assessment of the anterior chamber angle configuration may be more reliable if performed after a short-term dark adaptation of 3 minutes, a study found.
Webinar: LENSTAR LS 900® The First Optical Biometer of the Entire Eye
In this international webinar “Best Practices for IOL Power Measurements – Advanced Optical Biometry: Better Outcomes” Warren E. Hill, MD (East Valley Ophthalmology, Mesa, Arizona), explains that the ever increasing patient expectations, which along wi…
Vision Problems Common After Glaucoma Surgery
More than half of people getting a certain type of glaucoma surgery may suffer from temporary, sometimes severe vision loss afterwards, suggests a new study. A smaller proportion — about 8 in every 100 — could have some degree of permanent vision los…
Lucentis receives Health Canada approval for treatment of retinal vein occlusion
Following a priority review, Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from retinal vein occlusion (RVO). This makes Lucentis the first approved treatment of its class in Canada for this debilitating con…
Regeneron Announces Clinical Presentations At ASRS 2011 Annual Meeting
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that clinical data from four separate clinical studies of EYLEA™ (aflibercept injection) will be presented at the upcoming American Society of Retina Specialists (ASRS) meeting on Sunday, Augus…
Study Focuses On Relationship Between Glaucoma And Diabetes, Hypertension
Many Americans suffer from diabetes and hypertension and, according to a study by researchers at the University of Michigan Kellogg Eye Center, these individuals may have an increased risk of developing open-angle glaucoma (OAG). Joshua D. Stein, M.D.,…